News >

Immunotherapy Approval Offers New Hope in CSCC

Jason M. Broderick @jasoncology
Published: Thursday, Nov 08, 2018

Anna C. Pavlick, BSM, MS, DO, MBA

Anna C. Pavlick, BSM, MS, DO, MBA

Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab (Libtayo) becoming the first agent specifically approved by the FDA for advanced CSCC, Anna C. Pavlick, BSM, MS, DO, MBA, said in a session at the 36th Annual CFS®.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x